Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) is a specialty pharmaceutical company headquartered in Lake Forest, Illinois. The company is dedicated to advancing patient care through the commercialization of differentiated products in the areas of neurology, orphan, and specialty medicines. Assertio's portfolio includes three FDA-approved products:
- Gralise: Extended-release tablets for the management of postherpetic neuralgia.
- CAMBIA: A solution for the acute treatment of migraine attacks with or without aura in adults.
- Zipsor: Liquid-filled capsules for the relief of mild to moderate pain.
In August 2023, Assertio completed the acquisition of Spectrum Pharmaceuticals, Inc., bringing the innovative ROLVEDON™ to its portfolio. This addition is poised to diversify Assertio’s revenue base and enhance its commercial capabilities. Despite some challenges, including competition from generic drugs, Assertio remains committed to leveraging its digital non-personal sales model to drive growth and efficiency.
Financially, Assertio reported substantial cash flow from operations and maintained a robust cash position. The company continues to explore strategic acquisitions and licensing opportunities to expand its portfolio and drive long-term growth. Recent leadership changes and the appointment of experienced executives underscore Assertio’s commitment to optimizing its commercial strategies and maintaining financial stability.
Assertio’s forward-looking strategy involves not only enhancing its current product offerings but also advocating for patient access to medications through legislative efforts. The company’s non-personal promotional model and strategic acquisitions ensure its adaptability in a competitive market. For more detailed financial data and corporate updates, visit Assertio's investor relations website.
Assertio Holdings and Cove have partnered to enhance patient access to CAMBIA (diclofenac potassium) and SPRIX (ketorolac tromethamine) through Cove’s telemedicine platform. This collaboration aims to facilitate consultations with licensed physicians who can prescribe these medications for migraine treatment and pain management. The initiative aligns with Assertio's strategy for digital engagement and direct-to-patient care models, potentially expanding their reach in the market and improving patient convenience.
Assertio Holdings, Inc. (NASDAQ: ASRT) will announce its first quarter 2021 financial results on May 6, 2021, after market close. Management will host a conference call at 4:30 p.m. ET to discuss these results. Investors can access the live webcast at Assertio's investor relations website. Assertio is recognized for its differentiated pharmaceutical products in neurology, hospital, and pain management, having experienced growth through licensing and acquisitions.
Assertio Holdings reported full-year 2020 net product sales of $93.5 million and pro forma revenue of $119.2 million, aligning with guidance. The company raised $45.3 million in cash through direct offerings, enhancing liquidity. Assertio achieved $40 million in annual cost savings and expects an additional $45 million post-restructuring. Significant debt repayment included $450.2 million in 2020. However, the company faces challenges due to COVID-19's impact on elective procedures and a decline in prescription volumes.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced that Dan Peisert, its President and CEO, will present at the 33rd Annual Roth Conference on March 15, 2021. The virtual presentation is scheduled for 5:00 pm ET and will be available via live audio webcast on the company's investor website. A replay will also be accessible post-event. Assertio specializes in bringing differentiated pharmaceutical products to market, focusing on neurology, hospital, and pain management.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced that it will release its fourth quarter and full year 2020 financial results on March 11, 2021, after market close. A conference call with management is scheduled for 4:30 p.m. Eastern Time on the same day. Assertio is noted for its differentiated pharmaceutical products in neurology, hospital, and pain and inflammation segments. Investors can access the live webcast and replay via the company’s investor website.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced the closure of a registered direct offering, raising approximately $34.3 million at $0.98 per share.
After fees, the net proceeds are about $32.1 million, meant for general corporate purposes and working capital.
The offering was made under an effective shelf registration statement and involved Roth Capital Partners as the placement agent.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced a securities purchase agreement with institutional investors to sell 35 million shares at $0.98 per share, raising approximately $34.3 million before expenses. The registered direct offering is set to close on February 12, 2021. Funds will be used for general corporate purposes. The offering falls under a shelf registration statement declared effective by the SEC on February 4, 2021. Roth Capital Partners is the sole placement agent for this transaction.
Assertio Holdings, Inc. (NASDAQ: ASRT) has completed a registered direct offering of common stock priced at $0.62 per share, totaling approximately $14 million in gross proceeds. After fees and expenses, net proceeds are expected to be around $13 million, which will be used for general corporate purposes, including working capital. This offering was conducted under an effective shelf registration statement filed with the SEC.
Assertio Holdings, Inc. (NASDAQ: ASRT) has announced a registered direct offering of 22,600,000 shares at a price of $0.62 per share, expected to close on February 9, 2021. The offering aims to raise approximately $14 million before fees. Proceeds will be allocated for general corporate purposes and working capital. Roth Capital Partners acted as the sole placement agent. This is being offered under a shelf registration statement filed with the SEC, and details will be available in a prospectus supplement.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced a Confidential Settlement Agreement with Navigators Specialty Insurance, resolving a dispute over coverage of opioid lawsuits against its subsidiary Assertio Therapeutics. Navigators will pay $5 million of its $10 million primary policy by February 17, 2021. Additionally, Assertio updated its restructuring cost estimate to $11-12 million, reflecting non-cash charges and a pending non-cash impairment charge of at least $9 million for Q4 2020.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
What products does Assertio Holdings, Inc. offer?
What is the significance of Assertio’s acquisition of Spectrum Pharmaceuticals?
How does Assertio promote its products?
What are some of Assertio's recent financial highlights?
Who are some of the key leadership figures at Assertio?
What challenges does Assertio face with generic competition?
What is Assertio’s strategy for long-term growth?
How can investors access information about Assertio?
What role does Assertio play in legislative advocacy?
What is Assertio’s approach to sales and marketing?
